Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma

2021 ◽  
Vol 94 ◽  
pp. 107467
Author(s):  
Tudor Mocan ◽  
Maria Ilies ◽  
Iuliana Nenu ◽  
Rares Craciun ◽  
Adelina Horhat ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Outcomes ◽  
Serum Levels ◽  
Post Treatment ◽  
Programmed Death Ligand 1 ◽  
Early Hepatocellular Carcinoma ◽  
Programmed Death

scholarly journals Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 212 ◽  
Author(s):  
Maria Tampaki ◽  
Evangelos Ionas ◽  
Emilia Hadziyannis ◽  
Melanie Deutsch ◽  
Katerina Malagari ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Immunity ◽  
Transarterial Chemoembolization ◽  
Univariate Analysis ◽  
Post Treatment ◽  
Immune Checkpoints ◽  
Programmed Death Ligand 1 ◽  
Advanced Hcc ◽  
Programmed Death ◽  
Domain 3

Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization.

scholarly journals Evaluation of hepatocellular carcinoma circulating tumor cells expressing programmed death-ligand 1

HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S2-S3 ◽  
Author(s):  
P. Winograd ◽  
S. Hou ◽  
C.M. Court ◽  
S. Sadeghi ◽  
R.S. Finn ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

Hepatology ◽  
2016 ◽  
Vol 64 (6) ◽  
pp. 2038-2046 ◽  
Author(s):  
Julien Calderaro ◽  
Benoît Rousseau ◽  
Giuliana Amaddeo ◽  
Marion Mercey ◽  
Cécile Charpy ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pathological Features ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Clinical And Pathological Features

scholarly journals Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant

2020 ◽  
Vol Volume 7 ◽  
pp. 385-401
Author(s):  
Chiao-Fang Teng ◽  
Tsai-Chung Li ◽  
Ting Wang ◽  
Tzu-Hua Wu ◽  
John Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
B Virus

scholarly journals The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Shukang He ◽  
Weichao Jiang ◽  
Kai Fan ◽  
Xiaobei Wang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Group Treatment ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Efficacy And Safety ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Programmed Death 1

BackgroundHepatocellular carcinoma (HCC) is often diagnosed at an advanced stage where only systemic treatment can be offered. The emergence of immune checkpoint inhibitors (ICIs) provides hope for the treatment of HCC. In this study, we performed a meta-analysis to provide evidence for the efficacy and safety of ICIs in the treatment of HCC.MethodsThe following databases and websites were searched: Embase, PubMed, Cochrane Library and ClinicalTrials.gov. The primary endpoints were response rate (RR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).ResultsFinally, twelve studies were included in this meta-analysis. When the corresponding outcome indicators and their 95% confidence intervals (CIs) were pooled directly, the overall RR, DCR, PFS and OS were 0.17 (0.15-0.19, I2 = 56.2%, P=0.009), 0.58 (0.55-0.61, I2 = 75.9%, P<0.001), 3.27 months (2.99-3.55, I2 = 73.0%, P=0.001), 11.73 months (10.79-12.67, I2 = 90.3%, P<0.001). Compared to the control group, treatment with ICIs significantly improved RR, PFS and OS, the OR and HRs were 3.11 (2.17-4.44, P<0.001), 0.852 (0.745-0.974, P=0.019) and 0.790 (0.685-0.911, P=0.001), respectively. However, no significant improvement in DCR was found in ICIs treatment in this meta-analysis.ConclusionHCC patients would benefit from ICIs treatment, however, more studies are needed in the future to provide more useful evidence for the treatment of HCC by programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors.

scholarly journals Are preoperative high soluble programmed death ligand 1 levels responsible for patients’ poor prognoses in hepato-biliary-pancreatic cancer?

2020 ◽  
Author(s):  
Rei Okada ◽  
Yuichiro Otsuka ◽  
Masaru Tsuchiya ◽  
Tetsuya Maeda ◽  
Jun Ishii ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pancreatic Cancer ◽  
Poor Prognosis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Prognostic Impact ◽  
Poor Overall Survival ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Normal Albumin ◽  
Worse Prognosis

Abstract Background Several reports showed that high soluble programmed death-ligand 1(sPD-L1) level was a risk factor for poor prognosis in various tumors. To date, the clinicopathologic and prognostic impact of sPD-L1 level in patients with hepato-biliary-pancreatic cancer have not been determined. Methods A total of 119 patients (66 patients with hepatocellular carcinoma, 23 patients with cholangiocarcinoma, 30 patients with pancreatic cancer) who were treated at the Toho University Omori Hospital (Tokyo, Japan) from 2008 to 2016 were retrospectively analyzed. sPD-L1 levels were measured using an enzyme-linked immunosorbent assay for PD-L1 to evaluate clinicopathologic and prognostic impact. Results sPD-L1 levels were significantly higher in low-albumin group than normal albumin group. According to stages in hepatocellular carcinoma and cholangiocarcinoma, there were no significant differences in sPD-L1 levels, which gradually increased according to stage in pancreatic cancer. Using a cut-off value of 81.6 pg/ml for sPD-L1level, the high sPD-L1 group showed significantly worse prognosis than the low sPD-L1 group in patients with pancreatic cancer. Multivariate analysis identified sPD-L1 level ≥ 81.6 mg/dl (p = 0.047) as an independent predictor of poor overall survival in patients with pancreatic cancer. Conclusion High sPD-L1 levels were independently associated with poor prognosis. However, this association in hepatocellular carcinoma or cholangiocarcinoma was not clear.

Sign in / Sign up

Export Citation Format

Share Document